Skip to main content

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1061 Accesses

Abstract

Advances in the treatment of childhood cancers and supportive care have resulted in marked improvements in survival rates. As of 2009, there were an estimated 363,000 survivors of childhood cancer in the United States; of these approximately 24 % have survived more than 30 years since their diagnosis, contributing to the growing number of long-term survivors of childhood and adult cancer in the United States (Mariotto et al. 2009). However, the use of chemotherapy, radiation, and/or surgery at an early age can contribute to complications that may not become apparent until years after the completion of therapy (Armenian and Robison 2013). A recent article from the Childhood Cancer Survivor Study (CCSS) cohort reported that two out of three survivors will develop a chronic health condition, and more than one-third will develop a condition that is severe or life-threatening (Oeffinger et al. 2006). To address the needs of this growing population, in 2005, the Institute of Medicine (IOM) published From Cancer Patient to Cancer Survivor: Lost in Transition, a report outlining the gaps in survivorship care. The report introduced the concept of survivorship care plans to summarize information critical to the individual’s long-term care, such as the cancer diagnosis, treatment, and potential consequences; the timing and content of follow-up visits; tips on maintaining a healthy lifestyle and preventing recurrent or new cancers; legal rights affecting employment and insurance; and the availability of psychological and support services (Hewitt et al. 2006). This report provided the basis for professional organizations including the Children’s Oncology Group, National Comprehensive Cancer Network and the American Society of Clinical Oncology to publish evidenced-based guidelines for survivorship care for cancer survivors. It is crucial for health-care professionals who care for cancer survivors at all stages of their survivorship to be familiar with actual and potential late effects survivors may experience throughout their lifetime.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aksnes LH, Bauer HC, Dahl AA, Fossa SD, Hjorth L, Jebsen N, Lernedal H, Hall KS (2009) Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: a Scandinavian sarcoma group study. Pediatr Blood Cancer 53:84–89

    Article  CAS  PubMed  Google Scholar 

  • Armenian SH, Robison LL (2013) Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects. Curr Opin Pediatr 25:16–22

    Article  PubMed Central  PubMed  Google Scholar 

  • Arndt C, Morgenstern B, Hawkins D, Wilson D, Liedtke R, Miser J (1999) Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 32:93–96

    Article  CAS  PubMed  Google Scholar 

  • Aulivola B, Hile CN, Hamdan AD, Sheahan MG, Veraldi JR, Skillman JJ, Campbell DR, Scovell SD, Logerfo FW, Pomposelli FB Jr (2004) Major lower extremity amputation: outcome of a modern series. Arch Surg 139:395–399, discussion 399

    Article  PubMed  Google Scholar 

  • Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB (2008) Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 26:1106–1111

    Article  CAS  PubMed  Google Scholar 

  • Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649–655

    Article  PubMed  Google Scholar 

  • Bhatia S, Sklar C (2002) Second cancers in survivors of childhood cancer. Nat Rev Cancer 2:124–132

    Article  PubMed  Google Scholar 

  • Bober SL, Zhou ES, Chen B, Manley PE, Kenney LB, Recklitis CJ (2013) Sexual function in childhood cancer survivors: a report from Project REACH. J Sex Med 10:2084–2093

    Article  PubMed  Google Scholar 

  • Chrischilles, EA, Mcdowell BD, Rubenstein L, Charlton M, Pendergast J, Juarez GY and Arora NK (2014) Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. J Cancer Surviv

    Google Scholar 

  • COG (2013) Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, version 4.0 [online]. Children’s Oncology Group, Monrovia, Available: www.survivorshipguidelines.org

    Google Scholar 

  • Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, Badner JA (2004) Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 64:4353–4356

    Article  CAS  PubMed  Google Scholar 

  • Eiser C, Darlington AS, Stride CB, Grimer R (2001) Quality of life implications as a consequence of surgery: limb salvage, primary and secondary amputation. Sarcoma 5:189–195

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ford JS, Kawashima T, Whitton J, Leisenring W, Laverdiere C, Stovall M, Zeltzer L, Robison LL, Sklar CA (2014) Psychosexual functioning among adult female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 32:3126–3136

    Article  PubMed  Google Scholar 

  • Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, Guerrero-Avendano G, Zapata-Tarres M, Medina-Sanson A (2007) Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 24:403–408

    Article  CAS  PubMed  Google Scholar 

  • Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, Smith SM, Stovall M, Hammond S, Robison LL, Oeffinger KC (2010) Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 102:1272–1283

    Article  PubMed Central  PubMed  Google Scholar 

  • Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426–433

    Article  CAS  PubMed  Google Scholar 

  • Grewal S, Merchant T, Reymond R, Mcinerney M, Hodge C, Shearer P (2010) Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Pediatrics 125:e938–e950

    Article  PubMed Central  PubMed  Google Scholar 

  • Hellmann K (2007) Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without evidence. J Clin Oncol 25:4689–4690, author reply 4690–1

    Article  PubMed  Google Scholar 

  • Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis IJ, Bailey CC (1991) Progressive renal toxicity due to ifosfamide. Arch Dis Child 66:966–970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hewitt ME, Ganz PA, Institute of Medicine (U.S.), American Society of Clinical Oncology (U.S.) (2006) From cancer patient to cancer survivor: lost in transition : an American Society of Clinical Oncology and Institute of Medicine Symposium. National Academies Press, Washington, D.C

    Google Scholar 

  • Hyppolito MA, De Oliveira JA, Rossato M (2006) Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol 263:798–803

    Article  PubMed  Google Scholar 

  • Janeway KA, Grier HE (2010) Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11:670–678

    Article  PubMed  Google Scholar 

  • Kaste SC, Neel MN, Rao BN, Thompson VF, Pratt CB (2001) Complications of limb-sparing procedures using endoprosthetic replacements about the knee for pediatric skeletal sarcomas. Pediatr Radiol 31:62–71

    Article  CAS  PubMed  Google Scholar 

  • Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596

    Article  PubMed  Google Scholar 

  • Koch Nogueira PC, Hadj-Aissa A, Schell M, Dubourg L, Brunat-Mentigny M, Cochat P (1998) Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 12:572–575

    Article  CAS  PubMed  Google Scholar 

  • Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J, Constine LS, Freeman CR, Friedman DL, Green DM, Marina N, Meadows AT, Neglia JP, Oeffinger KC, Robison LL, Ruccione KS, Sklar CA, Hudson MM (2004) Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22:4979–4990

    Article  PubMed  Google Scholar 

  • Landier W, Wallace WH, Hudson MM (2006) Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening. Pediatr Blood Cancer 46:149–158

    Article  PubMed  Google Scholar 

  • Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903–909

    Article  CAS  PubMed  Google Scholar 

  • Lewis MJ, Dubois SG, Fligor B, Li X, Goorin A, Grier HE (2009) Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387–391

    Article  PubMed  Google Scholar 

  • Lipshultz SE, Lipsitz SR, Orav EJ (2007) Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without compelling evidence. J Clin Oncol 25:3179, author reply 3180

    Article  PubMed  Google Scholar 

  • Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G (1999) Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39:454–461

    CAS  PubMed  Google Scholar 

  • Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C (2012) Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983–2006). Cancer 118:5050–5059

    Article  PubMed  Google Scholar 

  • Marina N, Hudson MM, Jones KE, Mulrooney DA, Avedian R, Donaldson SS, Popat R, West DW, Fisher P, Leisenring W, Stovall M, Robison LL, Ness KK (2013) Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma: a report from the childhood cancer survivor study. Arch Phys Med Rehabil 94:1062–1073

    Article  PubMed Central  PubMed  Google Scholar 

  • Mariotto AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L, Feuer EJ (2009) Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 18:1033–1040

    Article  PubMed  Google Scholar 

  • Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD (2009) Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27:2356–2362

    Article  PubMed Central  PubMed  Google Scholar 

  • Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109:896–904

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nagarajan R, Neglia JP, Clohisy DR, Robison LL (2002) Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol 20:4493–4501

    Article  PubMed  Google Scholar 

  • Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N (2011) Twenty years of follow-up of survivors of childhood osteosarcoma. Cancer 117:625–634

    Article  PubMed Central  PubMed  Google Scholar 

  • NCCN. 07/22/2014. NCCN clinical practice guidelines in oncology: survivorship; version 2.2014 [Online]. Available: www.nccn.org

  • Neuwelt EA, Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig GW, Muldoon LL (2006) Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer 47:174–182

    Article  PubMed  Google Scholar 

  • Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, De Vathaire F (2009) Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 27:5350–5355

    Article  CAS  PubMed  Google Scholar 

  • Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582

    Article  CAS  PubMed  Google Scholar 

  • Oeffinger KC, Hudson MM, Landier W (2009) Survivorship: childhood cancer survivors. Prim Care 36:743–780

    Article  PubMed  Google Scholar 

  • Oeffinger KC, Argenbright K, McCabe M, Ng A, Rodriguez MA, Surbone A, Waisman J (2014) Providing high quality survivorship care in practice: an ASCO guide

    Google Scholar 

  • Refaat Y, Gunnoe J, Hornicek FJ, Mankin HJ (2002) Comparison of quality of life after amputation or limb salvage. Clin Orthop Relat Res 397:298–305

    Article  PubMed  Google Scholar 

  • Renard AJ, Veth RP, Schreuder HW, van Loon CJ, Koops HS, van Horn JR (2000) Function and complications after ablative and limb-salvage therapy in lower extremity sarcoma of bone. J Surg Oncol 73:198–205

    Article  CAS  PubMed  Google Scholar 

  • Rybak LP, Ramkumar V (2007) Ototoxicity. Kidney Int 72:931–935

    Article  CAS  PubMed  Google Scholar 

  • Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226:157–167

    Article  CAS  PubMed  Google Scholar 

  • Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH (1989) Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754–760

    CAS  PubMed  Google Scholar 

  • Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677–1682

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Stohr W, Paulides M, Bielack S, Jurgens H, Koscielniak E, Rossi R, Langer T, Beck JD (2007) Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48:140–147

    Article  CAS  PubMed  Google Scholar 

  • Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 25:493–500

    Article  CAS  PubMed  Google Scholar 

  • Veenstra KM, Sprangers MA, van der Eyken JW, Taminiau AH (2000) Quality of life in survivors with a Van Ness-Borggreve rotationplasty after bone tumour resection. J Surg Oncol 73:192–197

    Article  CAS  PubMed  Google Scholar 

  • von Hoff DD, Penta JS, Helman LJ, Slavik M (1977) Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 61:745–748

    Google Scholar 

  • Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-Mcclure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, Horowitz ME (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362–372

    CAS  PubMed  Google Scholar 

  • Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222–2232

    Article  CAS  PubMed  Google Scholar 

  • Zebrack BJ, Foley S, Wittmann D, Leonard M (2010) Sexual functioning in young adult survivors of childhood cancer. Psychooncology 19:814–822

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stacy L. Whiteside CPNP-AC .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Whiteside, S.L., Audino, A.N. (2015). Survivorship. In: Cripe, T., Yeager, N. (eds) Malignant Pediatric Bone Tumors - Treatment & Management. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18099-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18099-1_16

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18098-4

  • Online ISBN: 978-3-319-18099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics